API | levopropoxyphene

levopropoxyphene (Novrad) Report issue

Small molecule Approved ^FDA

ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW

LEVOPROPOXYPHENE is an antitussive drug, one of enantiomer of propoxyphene. Pdropoxyphene is an analgesic in the opioid category, patented in 1955 and manufactured by Eli Lilly and Company. Pdropoxyphene is intended to treat mild pain and also has antitussive (cough suppressant) and local anaesthetic effects. ^NCATS

Chemistry

SMILES: CCC(=O)O[C@](CC1=CC=CC=C1)([C@@H](C)CN(C)C)C2=CC=CC=C2
InChIKey: XLMALTXPSGQGBX-PGRDOPGGSA-N
Mol. Mass: 339.4712
ALogP: 4.28 Partition coefficient
ChEMBL Molecules:

propoxyphene

levopropoxyphene napsylate

levopropoxyphene

More Chemistry

Pharmacology

Mechanism of Action:
- Cannabinoid receptor 1 (Homo sapiens) ^UniProt
- Mu-type opioid receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Oral
Pro Drug: No

Organizations (1)

Research & Development (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (1)

Pain (approved 1962)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue